Hedrich, Christian

Lieder der Romantik = Songs of the romantic era by Julia Hamari( Recording )

18 editions published between 1982 and 1994 in 3 languages and held by 45 WorldCat member libraries worldwide

Streichquartette by Kurt Albrecht( Recording )

3 editions published between 1976 and 1985 in German and No Linguistic content and held by 4 WorldCat member libraries worldwide

COVID-19: Behandlungsstrategien der deutschsprachigen Kinderrheumatologen Ergebnisse einer Online-Umfrage = COVID-19: treatment strategies of German-speaking pediatric rheumatologists : results of an online survey by Alexander Janda( )

1 edition published in 2020 in German and held by 3 WorldCat member libraries worldwide

Abstract: Background<br>Reliable data on the course and treatment of pediatric COVID-19 ("corona virus disease 2019") in immunosuppressed patients with rheumatic diseases are missing.<br><br>Aim<br>Delineation of individual strategies of the members of the Society for Pediatric Rheumatology (GKJR) in cases of COVID-19.<br><br>Methods<br>In May 2020 all GKJR members were invited to take part in an online survey. Opinion data regarding an approach using disease-modifying anti-rheumatic drugs (DMARD) in cases of COVID-19 as well as the readiness to use new therapeutic agents in patients in different stages of the disease were collected.<br><br>Results<br>A total of 71 respondents (27.3% of all contacted pediatric rheumatologists) took part in the survey. Of these 28.2% had treated patients with COVID-19. Over 95% of the respondents did not support a preventive adaptation of the anti-rheumatic treatment during the SARS-CoV-2 pandemic. In the case of outpatients under immunosuppression with proven COVID-19 more than 50% of the respondents would refrain from administering intravenous high-dose steroids, cyclophosphamide, anti-CD20 antibodies as well as BAFF, CTLA-4 and TNF-alpha blockades. Conversely, >70% of the respondents would continue the treatment with nonsteroidal anti-inflammatory drugs, hydroxychloroquine (HCQ), oral steroids, mycophenolate, IL-1 blockade and immunoglobulins (Ig). In the case of inpatients 74.6% of respondents would consider targeted COVID-19 treatment. In stable patients with oxygen treatment (stage I) HCQ (18.3%), azithromycin (16.9%) and Ig (9.9%) were most frequently used. In cases of early signs (stage II) or a manifest cytokine storm (stage III) anakinra (40.8% for stage II and 46.5% for stage III), tocilizumab (26.8% and 40.8%, respectively), steroids (25.4% and 33.8%, respectively) and remdesivir (29.6% and 38.0%, respectively) were most frequently used. The need for a personalized approach based on the current clinical situation was emphasized by many respondents.<br><br>Conclusion<br>The currently low prevalence of COVID-19 in Germany limits the general clinical experience. Therefore, the presented results have to be interpreted with caution and mostly as hypothetical treatment considerations. It is to be expected that there will always be a limited amount of evidence on pediatric COVID-19; therefore, a continuous and critical exchange of expert opinions on the treatment strategies is important

Outcome of chronic granulomatous disease - conventional treatment vs stem cell transplantation by Cinzia Dedieu( )

1 edition published in 2021 in English and held by 3 WorldCat member libraries worldwide

Abstract: Background<br>Hematopoietic stem cell transplantation (HSCT) can cure chronic granulomatous disease (CGD), but it remains debated whether all conventionally treated CGD patients benefit from HSCT.<br><br>Methods<br>We retrospectively analyzed 104 conventionally treated CGD patients, of whom 50 patients underwent HSCT.<br><br>Results<br>On conventional treatment, seven patients (13%) died after a median time of 16.2 years (interquartile range [IQR] 7.0-18.0). Survival without severe complications was 10 ± 3% (mean ± SD) at the age of 20 years; 85% of patients developed at least one infection, 76% one non-infectious inflammation. After HSCT, 44 patients (88%) were alive at a median follow-up of 2.3 years (IQR 0.8-4.9): Six patients (12%) died from infections. Survival after HSCT was significantly better for patients transplanted ≤8 years (96 ± 4%) or for patients without active complications at HSCT (100%). Eight patients suffered from graft failure (16%); six (12%) developed acute graft-vs-host disease requiring systemic treatment. Conventionally treated patients developed events that required medical attention at a median frequency of 1.7 (IQR 0.8-3.2) events per year vs 0 (IQR 0.0-0.5) in patients beyond the first year post-HSCT. While most conventionally treated CGD patients failed to thrive, catch-up growth after HSCT in surviving patients reached the individual percentiles at the age of diagnosis of CGD.<br><br>Conclusion<br>Chronic granulomatous disease patients undergoing HSCT until 8 years of age show excellent survival, but young children need more intense conditioning to avoid graft rejection. Risks and benefits of HSCT for adolescents and adults must still be weighed carefully

Therapeutic approaches to pediatric COVID-19: an online survey of pediatric rheumatologists by Ales Janda( )

1 edition published in 2021 in English and held by 3 WorldCat member libraries worldwide

Abstract: Data on therapy of COVID-19 in immunocompetent and immunosuppressed children are scarce. We aimed to explore management strategies of pediatric rheumatologists. All subscribers to international Pediatric Rheumatology Bulletin Board were invited to take part in an online survey on therapeutic approaches to COVID-19 in healthy children and children with autoimmune/inflammatory diseases (AID). Off-label therapies would be considered by 90.3% of the 93 participating respondents. In stable patients with COVID-19 on oxygen supply (stage I), use of remdesivir (48.3%), azithromycin (26.6%), oral corticosteroids (25.4%) and/or hydroxychloroquine (21.9%) would be recommended. In case of early signs of "cytokine storm" (stage II) or in critically ill patients (stage III) (a) anakinra (79.5% stage II; 83.6% stage III) or tocilizumab (58.0% and 87.0%, respectively); (b) corticosteroids (oral 67.2% stage II, intravenously 81.7% stage III); (c) intravenous immunoglobulins (both stages 56.5%); or (d) remdesivir (both stages 46.7%) were considered. In AID, > 94.2% of the respondents would not support a preventive adaptation of the immunomodulating therapy. In case of mild COVID-19, more than 50% of the respondents would continue pre-existing treatment with immunoglobulins (100%), hydroxychloroquine (94.2%), anakinra (79.2%) or canakinumab (72.5%), or tocilizumab (69.8%). Long-term corticosteroids would be reduced by 26.9% (< = 2 mg/kg/d) and 50.0% (> 2 mg/kg/day), respectively, with only 5.8% of respondents voting to discontinue the therapy. Conversely, more than 75% of respondents would refrain from administering cyclophosphamide and anti-CD20-antibodies. As evidence on management of pediatric COVID-19 is incomplete, continuous and critical expert opinion and knowledge exchange is helpful

Whenever I seem to be far away by Terje Rypdal( Recording )

3 editions published in 1974 in Undetermined and English and held by 3 WorldCat member libraries worldwide

Werke by Arthur Dangel( )

2 editions published in 1992 in German and held by 2 WorldCat member libraries worldwide

Les Grandes cantates 6. Cantate BWV 4, 18, 54, 71, 106, 131, 143, 172, 182, 196( Recording )

1 edition published in 1976 in Undetermined and held by 2 WorldCat member libraries worldwide

Kammermusik by Arthur Dangel( Recording )

in German and Undetermined and held by 2 WorldCat member libraries worldwide

Die Streichtrios by Johann Nepomuk David( Recording )

1 edition published in 1988 in Undetermined and held by 2 WorldCat member libraries worldwide